Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 32, Issue 12, Pages 683-685Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2011.09.005
Keywords
-
Categories
Ask authors/readers for more resources
Recent reports suggest that R&D productivity in the pharmaceutical industry can be strengthened by reducing costs both in the early phase and, mostly, in the clinical phase of drug discovery. However, a cost benefit probabilistic analysis reveals that despite high costs, the clinical phase shows healthy productivity, whereas the early phase, particularly lead optimization, exhibits very low productivity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available